Overview

Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia

Status:
Terminated

Trial end date:
2008-07-01

Target enrollment:

Participant gender:

Summary

This is a phase I trial in patients with relapsed or refractory leukemia of a human monoclonal antibody that kills B cell acute lymphoblastic leukemia. The trial will study the safety, pharmacokinetics, and anti-tumor activity of the antibody given as a single agent and with vincristine.

Phase:

Phase 1

Details

Lead Sponsor:

Clare Twist

Collaborator:

National Institutes of Health (NIH)

Treatments:

Vincristine